Products for Research Use Only
RegisterLogin

Diiodohydroxyquinoline

CAT: 0804-HY-B1400-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B1400-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Diiodohydroxyquinoline (Iodoquinol, 5,7-Diiodo-8-hydroxyquinoline, 5,7-Diiodo-8-quinolinol) has an orally active and satisfactory antiparasitic properties. Diiodohydroxyquinoline exhibits mutagenic potential in mice and potent anti-SARS-CoV-2 activity with an EC50 value of 1.38 μM in VeroE6 cells. Diiodohydroxyquinoline's antimutagen is ascorbic acid. Diiodohydroxyquinoline is promising for research in inflammationin, testinal amebiasis, amebic liver abscess and chronic nonspecific diarrheas[1][2][3][4][5].
CAS Number
83-73-8
Product Name Alternative
Iodoquinol; 5,7-Diiodo-8-hydroxyquinoline; 5,7-Diiodo-8-quinolinol
UNSPSC
12352005
Hazard Statement
H302, H318
Target
Parasite; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Diiodohydroxyquinoline.html
Purity
99.0
Solubility
DMSO : 20.83 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL
Smiles
OC1=C2N=CC=CC2=C(I)C=C1I
Molecular Formula
C9H5I2NO
Molecular Weight
396.95
Precautions
H302, H318
References & Citations
[1]Martínez-Castillo M, et al. Flavonoids as a Natural Treatment Against Entamoeba histolytica. Front Cell Infect Microbiol. 2018 Jun 22;8:209.|[2]Ghaskadbi S, et al. In vivo antimutagenic effect of ascorbic acid against mutagenicity of the common antiamebic drug diiodohydroxyquinoline[J]. Mutat Res. 1989 Mar;222 (3) :219-22. |[3]Yuan S, et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system[J]. Pharmacol Res. 2020 Sep;159:104960.|[4]Chandramohan H. Asrani, et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a primary care physician research group study[J]. 1995 July, 56 (7) : 678-683.|[5]Cohlan SQ. Chronic nonspecific diarrhea in infants and children treated with diiodohydroxyquinoline. Pediatrics. 1956 Sep;18 (3) :424-32.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
BUP19778-01Diiodohydroxyquinoline
19022-015,7-Diiodo-8-Quinolinol (Diiodohydroxyquinoline, Iodoquinol) ExiPlus, 96.5%

Popular Products